Nextgen Share Discussion Threads

[bobby.ifa] 04/4/2011 13:55

All they're doing is jacking up the offer.Bid needs to follow, otherwise its just daylight sodding robeery on the spread. Suck a few buyers in then drop the offer again & trap some poor sod in for an age.

[lady gaga] 04/4/2011 13:44

Lets c what happens guys but its looking good.

LG

[bobby.ifa] 04/4/2011 13:39

I wanted 1 million but could only get 500k & then it jumped up before I could buy further. Does like to move this one.

[george57] 04/4/2011 13:38

TDW will now sell you nothing.. looks like we could see a move soon.

[sonicx] 04/4/2011 13:37

Free shares are scarce so any positive BUYS will move the price quickly IMO

[george57] 04/4/2011 13:32

No discounted shares available 0.34p for 500k, 0.365p for just 1m, TDW.

[lady gaga] 04/4/2011 13:30

It moved 220% in a half hour.

[george57] 04/4/2011 13:28

Some of that PYC & VAL gravy is starting to work its way into NGG, last time we saw buying here it hit 0.5p very quickly..

[sonicx] 04/4/2011 13:27

Looking really good, could we get past 0.5p and stay there this time?

[lady gaga] 04/4/2011 12:17

Looking good for the rest of the day

[stephanie_m] 04/4/2011 08:38

Additional MM in NGG shares from this morning.

No 6 MM's

s

[lady gaga] 01/4/2011 11:10

PYC RNS just out great results

It will prob help us also.

[lady gaga] 29/3/2011 14:33

Coming to life fingers crossed.

[moochy] 28/3/2011 15:55

Just bought 500,000 shares at .3115p, showing as a sell. MMs dropped bid to .28p right after I bought. MMs trying to get their greasy fingers in here.

[stephanie_m] 25/3/2011 07:39

I continue to add here.

s

[knowing] 21/3/2011 20:30

It's great to see these small caps recovering. I was in here at 0.06 for 2M+ bit exited too early. Looking around one microcap which stands out now is MHG. Worth tucking a few of those away too.

[lady gaga] 20/3/2011 16:16

Glad 2 here positive comments guys.

[stephanie_m] 20/3/2011 13:37

"1p here we come".

I am accumulating these shares at current price. Excellent prospect for 100% rise this year.

s

[moochy] 20/3/2011 13:06

In my opinion .3p is what they value the company, hence not more and not less unless major contracts are going to be won hence more profit increasing the value of NGG, or if they get bought out at a premium.

[lady gaga] 20/3/2011 10:24

Yea .3p so I suppose they cannot drop below .3p.
These were trading at .28p last week at 1 point so I suppose it's still an improvement on that.
Im still going to hold this out until the big news arrives.

1p here we come.

Glta

[34trader] 19/3/2011 17:35

Positive RNS.
Nothing wrong on issuing options to staff based on agreed performances.

Also brokers prepared to accept shares in lieu of payment @.3p

[loveabul] 19/3/2011 09:28

What do people think of the late RNS friday.

Is it good or bad news.



Regulatory Story
Go to market news section

Company NextGen Group PLC
TIDM NGG
Headline Grant of Options
Released 17:04 18-Mar-2011
Number 2618D17



RNS Number : 2618D
NextGen Group PLC
18 March 2011

NextGen Group plc (the "Company")

Grant of Options

Ann Arbor, Michigan, US, and London, UK, 18 March 2011 - NextGen Group plc (AIM:NGG) is pleased to announce that on 18 March 2011 it approved an option plan totaling 2,584,014,751 options for management and employees of NGG and Next Gen Sciences Inc. (NGS) in the UK and the US. NextGen Sciences Inc., which is a subsidiary of NextGen Group, is a leader in biomarker discovery, measurement and qualification.

The scheme has been created as an incentive stock option plan with clear near-term and long-term goals to be attained by management and employees for the options to vest, and represents an important part of the company's new biomarker business strategy. Approximately 30% of the total option plan (667,374,336 unissued shares currently authorized for allotment) vest pro rata to each option holder on 18 March 2011 and the remaining options will vest later and will be exercisable subject to satisfaction of objective criteria such as total profitability, sales and biomarker assay development. This remainder of the option plan will be issued and granted after approval at NGG'S AGM, expected to be held at the end of April this year.

The options have an exercise price of 0.1p except for US employees where, for tax reasons, the exercise price has been set as the VWAP of shares in the Company for the 30 days prior to board approval, that is 0.33p., All options have to be exercised before 18 March 2021 whereafter they will lapse. The total option plan corresponds to 19.8% of the current fully diluted share capital. The total number of options held following this grant is set out below:





Total holding as at 18 March 2011

Management and Board



Klaus Rosenau, Chairman & CEO, NGG
273,685,139

Leif Hamø, CFO, NGG
117,293,631

Barry McAleer, CEO, NGS
117,293,631

Thomas Borcholte, non-executive director, NGG
10,500,000






Company Secretary



Thomas Przygoda
15,000,000






Other employees



UK employees
14,911,131

US employees
60,150,000






Other



OAR GmbH1
33,715,804






Total
642,549,336


1 OAR GmbH is a German consultancy company that is doing consultancy work for NextGen Group.

None of the above people or entities have options before this grant.

Furthermore it has been agreed that NextGen Group Plc will pay its broker Dowgate Capital Stockbrokers Limited for services provided in 2010 and the first half of 2011 in shares in the Company, such shares to be issued at a price of 0.3p for 2,400,000 shares. Accordingly, application will be made for a total of 2,400,000 ordinary shares to be admitted to trading on AIM and trading is expected to commence on 24 March 2011.



- ENDS -



For more information please contact :



NextGen Group Plc.

Klaus Rosenau, Chairman and CEO

[e-mail]

[phone]



Seymour Pierce

Jonathan Wright, Nicola Marrin

[phone]



Notes to Editors



NextGen Sciences Inc. (Ann Arbor, MI, USA) is the subsidiary of NextGen Group Plc., London, UK (AIM: NGG). It provides pharmaceutical, biotechnology and diagnostic companies with rapid and quantitative protein biomarker discovery, measurement and qualification services using mass spectrometry technology. With a rise in the industry focus on personalised medicine and cost-effectiveness, biomarkers are playing an increasing important role in drug discovery, development and patient access, as well as healthcare delivery. The global market for biomarkers is expected to grow to $12.8bn by 2012 (BCC Research), with those for neurological disorders ($3.5bn by 2015, Espicom Healthcare) and oncology ($9.5bn by 2014, www.marketsandmarkets.com) playing an important role. NextGen Sciences' products include discoveryexpress for discovery of new biomarkers and targets, assayexpress for assay development and testingexpress for biomarker qualification. For more information visit www.nextgensciences.com




This information is provided by RNS
The company news service from the London Stock Exchange

END


RDSSFDFWAFFSESD



London Stock Exchange plc is not responsible for and does not check content on this Website. Website users are responsible for checking content. Any news item (including any prospectus) which is addressed solely to the persons and countries specified therein should not be relied upon other than by such persons and/or outside the specified countries. Terms and conditions, including restrictions on use and distribution apply.

©2009 London Stock Exchange plc. All rights reserved


Regulatory